United States Adalimumab Biosimilar Market Size & Outlook, 2026-2034
United States Adalimumab Biosimilar Market Insights
- Deep Market Insights analysis indicates that the United States Adalimumab Biosimilar Market size, valued at USD 822.39 Million in 2025, is expected to expand to USD 1399.26 Million by 2034.
- The United States market is forecasted to expand at a CAGR of 6.14% spanning 2026–2034.
- Adalimumab biosimilars held the leading position among By Type segments in 2025, based on market size.
- Interchangeable biosimilars is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.
![United States Adalimumab Biosimilar Market Size, Share & Growth Report By [2034]](https://deepmarketinsights.com/uploads/charts/united-states-adalimumab-biosimilar-market-united-states-by-type-509446.png)
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United States accounted for 29.06% of the global Adalimumab Biosimilar Market size.
- By 2034, United States is expected to lead the global Adalimumab Biosimilar Market in terms of market size.
- Within North America, United States is projected to dominate the regional Adalimumab Biosimilar Market size by 2034.
- Canada is identified as the fastest-growing market in North America, anticipated to reach USD 530.21 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 822.39 Million |
| Market Size In 2034 | USD 1399.26 Million |
| Largest segment | Adalimumab biosimilars |
| Units | Revenue in USD Million |
| CAGR | 6.14% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Indication |
|
| By Route of Administration |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Adalimumab Biosimilar Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab biosimilars | XX.x | XX.x | XX.x | 335.13 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Interchangeable biosimilars | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| High-concentration formulations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Low-concentration formulations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States Adalimumab Biosimilar Market By Indication 2026-2034 (USD Million)
| By Indication | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | XX.x | XX.x | XX.x | 384.72 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Psoriasis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Crohn’s disease | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ulcerative colitis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States Adalimumab Biosimilar Market By Route of Administration 2026-2034 (USD Million)
| By Route of Administration | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subcutaneous | XX.x | XX.x | XX.x | 370.41 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prefilled syringes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Auto-injectors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospital administration | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States Adalimumab Biosimilar Market By End User 2026-2034 (USD Million)
| By End User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 351.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Homecare | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.